Valuation: Charles River Laboratories International, Inc.

Market Cap 1.1TCr 971.35Cr 902.38Cr 829.94Cr 1.56TCr 1,07000Cr 1.58TCr 11TCr 4.21TCr 52TCr 4.15TCr 4.06TCr 1,81000Cr P/E 2026 *
37.4x
P/E 2027 * 25.1x
Enterprise Value 1.29TCr 1.13TCr 1.05TCr 966.22Cr 1.81TCr 1,24500Cr 1.84TCr 13TCr 4.9TCr 61TCr 4.83TCr 4.72TCr 2,10700Cr EV / Sales 2026 *
3.34x
EV / Sales 2027 * 3.17x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
20/07 Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… Zonebourse
13/07 BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 MT
13/07 Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating MT
13/07 Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics MT
13/07 Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches CI
13/07 Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating MT
09/07 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
07/07 Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
02/07 Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing MT
01/07 Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating MT
18/06 Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise CI
18/06 Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating MT
18/06 Charles River Laboratories Shares Rise After Morgan Stanley Upgrade MT
1 day+4.84%
1 week+0.06%
Current month+1.10%
1 month+22.88%
3 months+36.69%
6 months+4.41%
Current year+14.94%
1 week 213.4
Extreme 213.4
238.85
1 month 202.78
Extreme 202.78
238.85
Current year 146.2
Extreme 146.195
238.85
1 year 144.26
Extreme 144.26
238.85
3 years 91.86
Extreme 91.8609
275
5 years 91.86
Extreme 91.8609
460.21
10 years 67.2
Extreme 67.2
460.21
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Date Insider Type Main position Quantity % Market Cap.
29/06/26 Sell

Director

-75,000 0.1557%
05/06/26 Don

Director

-3,66,722 0.7613%
05/06/26 Don

Chief Executive Officer

-6,772 0.0141%
Change 5-day change 1-year change 3-year change Capi.($)
+4.84%+0.06%+36.52%+11.10% 1.05TCr
+1.08%-5.74%-4.98%+10.45% 4.61TCr
+3.13%+5.34%+402.93%+605.08% 3.89TCr
+2.14%+2.95%+10.83%+65.45% 3.56TCr
+4.43%-1.51%+6.73%-9.17% 3.31TCr
+1.23%-2.05%+0.56%+30.76% 2.64TCr
+0.29%-2.75% - - 1.66TCr
+14.71%+12.62%+38.50%+146.99% 1.51TCr
-6.32%-4.86%+4.36%+8.22% 1.41TCr
+1.82%+0.19%+1.45%-30.74% 1.28TCr
Average +2.59%-0.81%+55.21%+93.13% 2.49TCr
Weighted average by Cap. +2.33%-1.41%+73.60%+124.33%

Financials

2026 *2027 *
Net sales 384.83Cr 338.45Cr 314.42Cr 289.18Cr 542.31Cr 37TCr 552.03Cr 3.76TCr 1.47TCr 18TCr 1.44TCr 1.41TCr 63TCr 392.31Cr 345.03Cr 320.53Cr 294.8Cr 552.85Cr 38TCr 562.76Cr 3.83TCr 1.5TCr 19TCr 1.47TCr 1.44TCr 64TCr
Net income 29Cr 25Cr 23Cr 21Cr 40Cr 2.76TCr 41Cr 278.58Cr 108.66Cr 1.35TCr 107.04Cr 104.73Cr 4.67TCr 42Cr 37Cr 34Cr 31Cr 59Cr 4.04TCr 60Cr 407.73Cr 159.03Cr 1.97TCr 156.67Cr 153.28Cr 6.84TCr
Net Debt 181.35Cr 159.5Cr 148.18Cr 136.28Cr 255.57Cr 18TCr 260.15Cr 1.77TCr 691.12Cr 8.57TCr 680.84Cr 666.11Cr 30TCr 138.52Cr 121.83Cr 113.18Cr 104.09Cr 195.21Cr 13TCr 198.71Cr 1.35TCr 527.89Cr 6.54TCr 520.03Cr 508.78Cr 23TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change Volume
23/26/23 $229.29 +4.84% 10,75,142
22/26/22 $218.70 -0.32% 5,70,783
21/26/21 $219.40 -0.14% 9,25,041
20/26/20 $219.70 -2.07% 9,53,020
17/26/17 $224.35 -2.10% 7,10,193
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
229.29USD
Average target price
230.93USD
Spread / Average Target
+0.72%

Quarterly revenue - Rate of surprise